InVitria Reveals Technology to Optimize Hybridoma Production P...( Article in S...),Health

Article in Spring edition of Bioprocessing Journal reports InVitria's recombinant human serum albumin (Cellastim) and recombinant lactoferrin (Lacromin) cell culture supplements optimize cell growth and productivity in hybridoma cells.

Fort Collins, CO (PRWEB) April 22, 2009-- Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria's cell culture supplements optimized cell growth and productivity of hybridoma cells.1 Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.

Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.

"This research incorporated classical media as well as several leading commercial media available on the market," said Dr. Steve Pettit, the project's lead researcher. "We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance."

Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).

"This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture," said InVitria President and CEO Scott Deeter. "Ce
'/>"/>